17 results about "NS3" patented technology

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The invention discloses an HCV recombinant fusion antigen protein which comprises a Core antigen epitope, an NS3 antigen epitope region and an NS5A antigen epitope of HCV which are connected in series, the amino acid sequence of the Core antigen epitope is as shown in SEQ ID NO: 1, the amino acid sequence of the NS3 antigen epitope is as shown in SEQ ID NO: 2, and the amino acid sequence of the NS5A antigen epitope is as shown in SEQ ID NO: 3. The HCV recombinant fusion antigen protein obtained by the invention has relatively high detection rate and specificity.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

The present invention pertains to compounds that inhibit Flavivirus NS2B-NS3 proteases and are potent and selective inhibitors of the West Nile virus and Zika virus. The compounds of the invention can be used alone or in combination with other agents to treat infections caused by these viruses. Additionally, the invention relates to pharmaceutical compositions containing these compounds.

The application provides a hepatitis C antibody detection antigen composition and application, kit and detection method thereof, relates to the antibody detection technical field, and the hepatitis C antibody detection antigen composition comprises a labeled recombinant antigen and a coated recombinant antigen, the amino acid sequence of the labeled recombinant antigen includes Trx and hepatitis C Core region, NS3 protein, NS4b protein dominant epitope and His tag, and the full-length sequence is shown as SEQ ID NO. 1. The labeled recombinant antigen used in the application is obtained by mutating 7 cysteines (C) into alanine (A) by amino acid mutation on the NS3 protein, reducing the aggregation and precipitation caused by disulfide bond of the recombinant protein, and improving the protein stability. When colloidal gold is used for antigen labeling, a secondary indirect labeling method is adopted, which is beneficial to the exposure of antigen epitopes, can improve the reaction sensitivity, and reduces the antibody missed detection.

Provided herein are compositions and methods that allow for controlled interaction between a target protein and a polypeptide to which a binding protein is fused. Compositions and methods utilize a target protein that binds to the hepatitis C virus protease inhibitor glaprevir to form a complex, and a Tn3 binding protein that specifically binds to the complex. The target protein is or is derived from a viral protease, such as an HCV NS3 / 4A protease.

The application provides application of embelin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the embelin has significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

Disclosed are bifunctional compounds (degraders) that target hepatitis C virus (HCV) NS3 / 4A for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat HCV infection and HCV-associated diseases or disorders.

The invention discloses a recombinant humanized anti-HCV NS3 monoclonal antibody, which comprises a light chain and a heavy chain, the monoclonal antibody is named as R-Anti-HCV-NS3-Ab, the amino acid sequence of the light chain is shown as SEQ ID NO.6, the amino acid sequence of the heavy chain is shown as SEQ ID NO.7, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.8. And the amino acid sequence of the heavy chain is as shown in SEQ ID NO.7. The recombinant humanized anti-HCV NS3 monoclonal antibody developed by the patent is designed based on an NS3 conserved epitope region, high affinity to main epidemic subtypes such as 1a, 1b, 2a, 3a, 4a and the like is ensured, and the broad-spectrum detection capability is ensured; through humanized transformation, anti-mouse antibody interference is reduced, false positive is avoided, and reagent stability is improved; multiple platforms such as chemiluminescence and ELISA are adapted; standardized production: a mammalian cell expression system is adopted, and the batch-to-batch consistency is obviously superior to that of a traditional polyclonal antibody; the quality control product disclosed by the invention can be used for accurately evaluating the sensitivity of an HCV antibody detection reagent, and is particularly suitable for regions with complicated genotypes.

This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.

The invention discloses an HDAC8 gene knockout MDBK cell line as well as a construction method and application thereof. According to the method, a CRISPR / Cas9 technology is utilized, specific gRNA is designed aiming at a second exon of a cattle HDAC8 gene, CRISPR expression plasmids are constructed, adherent MDBK cells are transfected, and HDAC8 homozygous frame-shift mutant cell lines KOHDAC8-1 (4bp deletion) and KOHDAC8-2 (1bp insertion) are obtained through puromycin screening and monoclonal separation. An identification result shows that HDAC8 knockout obviously promotes replication of the bovine viral diarrhea virus (BVDV), the expression level of NS3 mRNA and protein of the virus is increased, the virus titer is obviously improved, and the cell growth rate is not obviously influenced. The cell line provided by the invention can be used as an efficient proliferation matrix of the BVDV, is used for producing inactivated vaccines for bovine viral diarrhea, and effectively improves the yield and quality of the vaccines.

The application belongs to the field of genetic engineering, and particularly relates to a construction method and application of a red fluorescent protein labeled recombinant blue tongue virus. The application inserts a red fluorescent protein label sequence (mScarlet3) between 158th and 159th amino acids of a wild type blue tongue virus NS3 protein, and obtains a NS3 labeled recombinant blue tongue virus BTV-1 / NS3-158mScarlet3. Compared with the wild type blue tongue virus, the recombinant NS3 protein can correctly express the red fluorescent protein, but does not affect the replication of the virus, and can be used for expression positioning and dynamic tracking of the NS3 protein in the BTV infected cell, interaction between the NS3 protein and the host protein, BTV neutralization test, antiviral drug screening and gene delivery and the like.

The application provides application of zinc undecylenate in preparation of a drug for resisting dengue virus, and uses zinc undecylenate as an inhibitor of NS2B-NS3 protease in the dengue virus, wherein the zinc undecylenate has good inhibitory activity on the NS2B-NS3 protease in the dengue virus, and the zinc undecylenate has various carriers and administration modes, is convenient to use, and is easy to obtain.

This invention discloses a method for screening drugs against Japanese encephalitis virus, which uses the main protease NS3 of Japanese encephalitis virus. pro The activity reporter plasmid and the main protease NS3 of Japanese encephalitis virus pro Expression plasmids were used to screen for drugs against Japanese encephalitis virus; NS3 pro Active reporter plasmids and NS3 pro The expression plasmid was co-transfected into HEK-293T cells. The fluorescence intensity of green fluorescent protein (EGFP) was detected using an inverted fluorescence microscope and a multi-functional microplate reader to predict NS3. pro The activity of NS3, the main protease of JEV, can be used to screen for its activity. pro The purpose of this invention is to screen anti-JEV compounds using active reporter plasmids. The inhibitory effect of the compounds can be observed more intuitively and easily by utilizing fluorescence intensity, providing a powerful tool for screening broad-spectrum anti-JEV compounds.

The application provides application of hypericin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the hypericin has a significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.